Approach of research on hepatitis viruse related diseases

( views:, downloads: )
ZHANG Nai-hong()
ZHU Xiao-fan()
Journal Title:
Volume 14, Issue 05, 2005
Key Word:


  • [1]Franzin F, Efremov D G, Pozzato G, ct al. Clonal B-cell expansion in peripheral blood of HCV-infected patients[J]. Br J Hematol, 1995, 90:548 -552.
  • [2]Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon with an anti-CD20[J]. Blood, 2003, 101: 3818-3826.
  • [3]Ferri C, Caracciolo F, Zignego A L, et al. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma[J]. Br J Hematol, 1994, 88:392-394.
  • [4]Morris J, Eddleston A, Crook T. Viral infection and cancer[J]. Lancet,1995, 346: 754-758.
  • [5]Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell nonHodgkin's lymphomas:an Italian multicenter case- control study [J].Blood, 2003, 102: 996-999.
  • [6]Hausfater P, Cacoub P, Sterkers Y, et al. Hepatitis C virus infection an lymphoproliferative diseases:prospective study on 1576 patients in France[J]. Am J Hematol, 2001, 67: 168-171.
  • [7]Ellis M, Rathaus M, Amiel A, et al. Monoclonal lymphocytes proliferation and bcl-2 rearrangement in essential mixed cryoglobulinemia[J].Eur J Clin Invest, 1995, 25: 833-837.
  • [8]Zuckerman E, Zuckerman T, Sahar D, et al. bcl-2 and immunoglobulin gene rearrangement in patients with HCV infection[J]. Br J Hematol, 2001, 112: 364-369.
  • [9]Ivnovski M, Silversti F, Pozzato G, et al. Somatic mutation,clonal diversity, and preferential expression of the VH51pl/Vlkv325 immunocytomas[J]. Blood, 1998, 91: 2433-2442.
  • [10]Zuckerman E, Zuckerman T. Hepatitis C and B-cell lymphoma:the hemato-hepatologist linkage[J]. Blood Reviews, 2002, 16:119-125.
  • [11]Ray R B, Meyer K, Ray R, et al. Suppression of apoptotic cell death by hepatitis C core protein[J]. Vorology, 1996, 226: 176-182.
  • [12]Levy S, Todd S C, Maecker H T, et al. CD81(TAPA- 1):a molecule involved in signal transduction and cell adhesion in the immune system [J]. Annu Rev lmmunol, 1998, 16: 89-106.
  • [13]De Re V, De Vita S, Marzotto A, et al. Sequence analysis of the immunoglobulin antigen reciptor of hepatitis C virus - associated nonHodgkin's lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type Ⅱ eryoglobulinemia[J]. Blood, 2000, 96: 3578-3584.
  • [14]Majumder M, Ghosh A K, Steele R, et al. Hepatitis C virus NS5A proein impairs TNF-mediated hepatic apoptosis, but nat by an antiFAS antibody, in transgenic mice[J]. Virology, 2002, 294: 94-105.
  • [15]Bianco E, Marcucci F, Mele A, et al. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B- cell nonHodgkin's lymphoma,and in myeloproliferative.diseases an Italian multi-center study[J]. Haematologica, 2004, 89:70-76.
  • [16]Sung V M H, Shimoidara S, Doughty A L, et al. Establishment of Bcell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro:the apoptotic effects of virus infection [J]. J Virol,2003, 77: 2134-2146.
  • [17]De Re V, De Vita S, Marzotto A, et al. Pre-malignant and malignant lymphoproliferations in an HCV-infected type Ⅱ mixed cryoglobulinemic patient are sequential phases of an antigen - driven pathological pricess[J]. Int J Cancer, 2000, 87:211-216.
  • [18]Silini E, Locasciulli A, Santoleri L, et al. Hepatitis C virus infection in a hematology ward:evidence for nosocomial transmission and impact on hematologic diseases outcome[J]. Haematologica, 2002, 87:1200-1208.
  • [19]Mazzaro C, Franzin F, Tulissi P, et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alfa-interferon therapy[J]. Cancer, 1996, 77: 2604-2613.
  • [20]Tursi A, Brandimarte G, Torello M, et al. Disappearance of gastric mucosa-associated lymphoid tissue in hepatitis C virus theraphy[J]. J Clin Gastroenterol, 2004, 38(4): 360-363.
  • [21]Charles S, Rabkin E, Beatriz H, et al. Prospective study of hepatitis C virus infection aa a risk factor for subsequent B - cell neoplasia [J].Blood, 2002, 99: 4240-4242.
  • [22]Ohsawa M, Shingu N, Miwa H, et al. Risk of non - Hodgkin's lymphoma in patients with patients C virus infection [J]. Int J Cancer,1999, 80: 237-239.
  • [23]Donald K, Strickland, Caroline A, et al. Hepatitis C infection among survivors of childhood cancer[J]. Blood, 2000, 95: 3065-3070.
  • [24]Elena S, Massimo C, Monica R, et al. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemaphiliaca infected with the hepatitis C virus[J]. Blood, 2003, 102: 78-82.
  • [25]Yeo W, Chan P K, Zhong S, et al. Frequency of hepatitis B virus reastivation in cancer patients undergoing cytotoxic chemotherapy:a prospective study of 626 patients with identification of risk factor[J]. J Med Virol, 2000, 62: 299-307.
  • [26]Kawatani T, Suou T, Tajima F, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies[J]. Eur J Haematol, 2001, 67: 45-50.
  • [27]Riccardo U, Rosa Z, Pasquale B, et al. Dual or single Hepatitis B and C virus infection in childhood cancer survivors:long- term follow-up and effect of interferon treatment[J]. Blood, 1999, 94:4046-4052.
  • [28]Cesaro S, Petris M G, Rossetti F, et al. Chronic hepatitis C virus infection after treatment for pediatric malignancy[J]. Blood, 1997, 90:1315.
  • [29]McMillian J S, Shaw T, Angus P W, et al. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro[J]. Hepatology, 1995, 22: 36-43.
  • [30]George K, Yu-hung L, Daniel Y. High hepatitis B virus (HBV) DNA virus load as the most important rist factor for HBV reactivation in patients positive for HBV surfase antigen undergoing autologous hematopoietic cell transplantation[J]. Blood, 2002, 99: 2324-2330.
  • [31]Somjee S, Pai S, Parikh P, et al. Passive active prophylaxis against Hepatitis B in childen with acute lymphoblastic leukemia [J]. Leuk Res, 2002, 26(11): 989-992.
  • [32]Heider U, Fleissner C, Zavrski I, et al. Treatment of refractory chronic lymphocytic leukemia with Campath - 1H in combination with lamivuding in chronic hepatitis B infection[J]. Eur J Haematol, 2004,72: 64-66.
  • [33]Armor J, Fazili J, Toubia N, et al. Remission of Natural- Killer Cell Lymphoma of the Liver With Anti - Hepatitis C Theraphy [J]. Am J Hematol, 2005, 78:211-215.
  • [34]张乃红,陈玉梅,邹尧,等.急性杂合性白血病伴慢性乙型肝炎病毒携带1例报告[J].中国小儿血液,2005,10(1):35-36.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615